<DOC>
	<DOCNO>NCT02581007</DOCNO>
	<brief_summary>This trial evaluate safety efficacy reduce intensity allogeneic HSCT partially HLA-mismatched first-degree relative utilize PBSC stem cell source . The primary objective study estimate incidence graft rejection acute GVHD . A secondary objective estimate incidence relapse , NRM , OS , chronic GVHD EFS .</brief_summary>
	<brief_title>RIC Transplant Using Haplo Donors</brief_title>
	<detailed_description>Patients receive haploidentical transpalnt use fludarabine melphalan prepartive regimen . Patients get cyclophosphamide day 3 &amp; 4 post-transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>No available match relate unrelated donor , OR match relate unrelated donor available time frame necessary perform potentially curative transplant Availability 3/6 5/6 match ( HLAA , B , DR ) relate donor ( donor must negative HLA crossmatch host vs. graft direction ) Karnofsky status â‰¥70 % One follow highrisk malignancy : 1 . Chronic Myelogenous Leukemia : Chronic myelogenous leukemia chronic phase , resistant intolerant available tyrosine kinase inhibitor ; Chronic myelogenous leukemia accelerate phase ; Chronic myelogenous leukemia blast crisis enter second chronic phase follow induction chemotherapy 2 . Acute Myelogenous Leukemia first great remission 3 . Myelodysplastic Syndrome least one following : treatmentrelated ; monosmy 7 , complex cytogenetics high risk karyotype ; IPSS score 1.0 great ; neutropenia cytopenia require transfusion respond therapy ; peripheral BM blast count &lt; 10 % ; CMML 4 . Acute lymphocytic leukemia/lymphoblastic lymphoma : 2nd subsequent complete remission ; first complete remission ; marrow blast &lt; 5 % , persistence minimal residual disease flow cytometry , cytogenetics , FISH 5 . Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia : previously treat disease either relapse failed respond adequately conventionaldose therapy include purine analog 6 . Hodgkin 's NonHodgkin 's Lymphoma ( include lowgrade , mantle cell , intermediategrade/diffuse ) : previously treat disease either relapse failed respond adequately conventionaldose therapy autologous transplantation 7 . Myeloproliferative disease ( myelofibrosis , CMML ) 8 . Multiple Myeloma relapse prior autologous transplant eligible allogeneic HSCT base risk factor exclude basis sex , racial , ethnic background poor cardiac function : leave ventricular ejection fraction &lt; 40 % poor pulmonary function : FEV1 FVC &lt; 50 % predict poor liver function : bilirubin &gt; 2 mg/dl ( due hemolysis , Gilbert 's primary malignancy ) poor renal function : Creatinine &gt; 2.0mg/dl creatinine clearance ( calculated creatinine clearance permit ) &lt; 40 mL/min base Traditional CockcroftGault formula : 140 age ( yr ) x Smaller Actual Weight v . Ideal Body Weight ( kg ) / 72 x Serum creatinine ( mg/dl ) HIVpositive prior allogeneic transplant woman childbearing potential currently pregnant practice adequate contraception debilitate medical psychiatric illness would preclude give informed consent receive optimal treatment followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CML</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>ALL</keyword>
	<keyword>CLL/CPL</keyword>
	<keyword>HD</keyword>
	<keyword>NHL</keyword>
	<keyword>MPS</keyword>
	<keyword>CMML</keyword>
	<keyword>MM</keyword>
</DOC>